These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3871787)

  • 1. Short-term 1,25-dihydroxyvitamin D3 administration raises serum osteocalcin in patients with postmenopausal osteoporosis.
    Zerwekh JE; Sakhaee K; Pak CY
    J Clin Endocrinol Metab; 1985 Mar; 60(3):615-7. PubMed ID: 3871787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a long-term treatment with 1,25-dihydroxyvitamin D3 on osteocalcin in postmenopausal osteoporosis.
    Caniggia A; Nuti R; Galli M; Loré F; Turchetti V; Righi GA
    Calcif Tissue Int; 1986 Jun; 38(6):328-32. PubMed ID: 3089554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,25-Dihydroxyvitamin D stimulation test for osteoblast function in normal and osteoporotic postmenopausal women.
    Duda RJ; Kumar R; Nelson KI; Zinsmeister AR; Mann KG; Riggs BL
    J Clin Invest; 1987 Apr; 79(4):1249-53. PubMed ID: 3494046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis.
    Caniggia A; Delling G; Nuti R; Lorè F; Vattimo A
    Acta Vitaminol Enzymol; 1984; 6(2):117-28. PubMed ID: 6388277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3.
    Gundberg CM; Cole DE; Lian JB; Reade TM; Gallop PM
    J Clin Endocrinol Metab; 1983 May; 56(5):1063-7. PubMed ID: 6601111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term 25-hydroxyvitamin D3 therapy in postmenopausal osteoporosis: demonstration of responsive and nonresponsive subgroups.
    Zerwekh JE; Sakhaee K; Glass K; Pak CY
    J Clin Endocrinol Metab; 1983 Feb; 56(2):410-3. PubMed ID: 6600460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ability of 25-hydroxyvitamin D3 therapy to augment serum 1,25- and 24,25-dihydroxyvitamin D in postmenopausal osteoporosis.
    Lawoyin S; Zerwekh JE; Glass K; Pak CY
    J Clin Endocrinol Metab; 1980 Mar; 50(3):593-6. PubMed ID: 6965678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dichotomy in the effects of 1,25 dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 on bone gamma-carboxyglutamic acid-containing protein in serum and bone in vitamin D-deficient rats.
    Wientroub S; Price PA; Reddi AH
    Calcif Tissue Int; 1987 Mar; 40(3):166-72. PubMed ID: 3105848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,25-Dihydroxyvitamin D3 modulates glucocorticoid-induced alteration in serum bone Gla protein and bone histomorphometry.
    Jowell PS; Epstein S; Fallon MD; Reinhardt TA; Ismail F
    Endocrinology; 1987 Feb; 120(2):531-6. PubMed ID: 3492365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of parathyroidectomy on circulating levels of 1 alpha,25-dihydroxyvitamin D and bone Gla protein in dialyzed patients.
    Fanti P; Smith AJ; Price PA; Reitz RE; Malluche HH
    J Clin Endocrinol Metab; 1986 May; 62(5):869-73. PubMed ID: 3485651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term course of 1,25(OH)2D3 stimulates osteoblasts but not osteoclasts in osteoporosis and osteoarthritis.
    Geusens P; Vanderschueren D; Verstraeten A; Dequeker J; Devos P; Bouillon R
    Calcif Tissue Int; 1991 Sep; 49(3):168-73. PubMed ID: 1933581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up.
    Coen G; Mazzaferro S; Bonucci E; Taggi F; Ballanti P; Bianchi AR; Donato G; Massimetti C; Smacchi A; Cinotti GA
    Kidney Int; 1985 Nov; 28(5):783-90. PubMed ID: 3878905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteocalcin (BGP) values in postmenopausal osteoporosis before and after treatment with calcitonin].
    Rico H; Cabranes JA; Núñez-Torrón M; Higueras JC; Hernández ER
    Med Clin (Barc); 1986 May; 86(19):791-3. PubMed ID: 3488474
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute effect of 1,25-dihydroxyvitamin D3, prednisone, and 1,25-dihydroxyvitamin D3 plus prednisone on serum osteocalcin in normal individuals.
    Nielsen HK; Brixen K; Kassem M; Mosekilde L
    J Bone Miner Res; 1991 May; 6(5):435-41. PubMed ID: 2068950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis.
    Gallagher JC; Riggs BL; DeLuca HF
    J Clin Endocrinol Metab; 1980 Dec; 51(6):1359-64. PubMed ID: 6255005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone and serum concentrations of osteocalcin as a function of 1,25-dihydroxyvitamin D3 circulating levels in bone disorders in rats.
    Lian JB; Carnes DL; Glimcher MJ
    Endocrinology; 1987 May; 120(5):2123-30. PubMed ID: 3494594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.
    Pak CY; Sakhaee K; Zerwekh JE; Parcel C; Peterson R; Johnson K
    J Clin Endocrinol Metab; 1989 Jan; 68(1):150-9. PubMed ID: 2909549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Gla protein messenger ribonucleic acid is regulated by both 1,25-dihydroxyvitamin D3 and 3',5'-cyclic adenosine monophosphate in rat osteosarcoma cells.
    Theofan G; Price PA
    Mol Endocrinol; 1989 Jan; 3(1):36-43. PubMed ID: 2464756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.